Alkermes
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
ALKS Key Statistics
Stock Snapshot
With a market cap of 4.83B, Alkermes(ALKS) trades at $29.26. The stock has a price-to-earnings ratio of 14.48.
On 2025-11-19, Alkermes(ALKS) stock moved within a range of $28.84 to $29.86. With shares now at $29.26, the stock is trading +1.5% above its intraday low and -2.0% below the session's peak.
Trading volume for Alkermes(ALKS) stock has reached 3.08M, versus its average volume of 3.84M.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
The stock's 52-week range extends from a low of $25.17 to a high of $36.45.
ALKS News
Truist raised the firm’s price target on Alkermes (ALKS) to $55 from $50 and keeps a Buy rating on the shares. Positive Vibrance-2 results materially de-risk th...
Avadel Pharmaceuticals (AVDL) announced that, following discussions and negotiations with H. Lundbeck on the terms of its proposal, its board of directors has d...
Danish drugmaker H. Lundbeck has made an unsolicited bid worth up to $2.25 billion for Avadel Pharmaceuticals. Carsten Snejbjerg/Bloomberg News Danish drugmake...
Analyst ratings
81%
of 16 ratingsMore ALKS News
Alkermes (ALKS) notes the announcement made by Avadel Pharmaceuticals (AVDL) regarding a possible offer by H. Lundbeck A/S to acquire all the issued and to be i...
Alkermes (ALKS) shared positive topline data from its Vibrance-2 phase 2 study evaluating alixorexton in narcolepsy type 2. The study showed clinically meaningf...
Bank of America Securities analyst Jason Gerberry maintained a Hold rating on Alkermes yesterday and set a price target of $34.00. Meet Your ETF AI Analyst Disc...
Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in n...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
In a report released today, Ami Fadia from Needham maintained a Buy rating on Alkermes, with a price target of $44.00. Meet Your ETF AI Analyst Discover how Tip...